Comparison of Recombinant Human Erytropoetin and Darbepoetin Alpha in Children
ConclusionDA therapy can be an alternative to rHuEPO in the treatment of anemia in pediatric CKD patients with its clinical efficacy, application convenience, patient compliance and tolerability. (Source: Pediatrics International)
Source: Pediatrics International - March 5, 2013 Category: Pediatrics Authors: Ceren Can, Sevinç Emre, Ilmay Bilge, Alev Yilmaz, Aydan Şirin Tags: Original Article Source Type: research
Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF)
Conclusion
The anaemic patients enrolled in RED-HF were older, moderately to markedly symptomatic, and had extensive co-morbidity. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - February 20, 2013 Category: Cardiology Authors: McMurray, J. J. V., Anand, I. S., Diaz, R., Maggioni, A. P., O'Connor, C., Pfeffer, M. A., Solomon, S. D., Tendera, M., van Veldhuisen, D. J., Albizem, M., Cheng, S., Scarlata, D., Swedberg, K., Young, J. B., on behalf of the RED-HF Committees Investigato Tags: CLINICAL TRIALS Source Type: research
Meta‐analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy‐induced anemia and mortality: individual patient data from Japanese randomized, placebo‐controlled trials
Summary
Erythropoiesis‐stimulating agents (ESAs) reduce the need for transfusions and improve the quality of life in patients receiving chemotherapy, but several clinical trials have suggested that ESAs may have a negative impact on survival. To evaluate the efficacy and safety of the ESAs, epoetin beta and darbepoetin alfa, including their impact on overall survival and thromboembolic events, we conducted an individual data‐based meta‐analysis of three randomized, placebo‐controlled trials studying Japanese patients with chemotherapy‐induced anemia. All trials were conducted in compliance with Good Clinical Prac...
Source: Cancer Science - January 17, 2013 Category: Cancer & Oncology Authors: Yasuo Ohashi, Yukari Uemura, Yasuhito Fujisaka, Toru Sugiyama, Hironobu Ohmatsu, Noriyuki Katsumata, Rumiko Okamoto, Nagahiro Saijo, Tomomitsu Hotta Tags: Original Article Source Type: research
The MAINTAIN study-managing hemoglobin variability with darbepoetin alfa in dialysis patients experiencing a severe drop in hemoglobin.
CONCLUSIONS: This observational study describes physicians' reactions to a drop in hemoglobin in clinical practice. Using darbepoetin alfa, the drop was generally compensated without leading to overcorrection.
PMID: 23299452 [PubMed - as supplied by publisher] (Source: Wiener Klinische Wochenschrift)
Source: Wiener Klinische Wochenschrift - January 9, 2013 Category: Journals (General) Authors: Watschinger B, Salmhofer H, Horn S, Neyer U, Wiesinger T, Wiesholzer M, Erb H, Jaeger C, Hemetsberger M, Rosenkranz AR Tags: Wien Klin Wochenschr Source Type: research
Hemoglobin Stability in Patients With Anemia, CKD, and Type 2 Diabetes: An Analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) Placebo Arm
Background:
Sparse data are available about the natural history of hemoglobin (Hb) level trends in contemporary patients with anemia, chronic kidney disease (CKD), and type 2 diabetes mellitus. We intended to describe Hb level trends over time with no or minimal administration of erythropoiesis-stimulating agents.
Study Design:
Prospective clinical trial cohort.
Setting & Participants:
2,019 individuals with type 2 diabetes, moderate anemia, and CKD from the placebo arm of the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) followed up for 2.3 years with an average of 32 monthly Hb level determinati...
Source: American Journal of Kidney Diseases - November 19, 2012 Category: Urology & Nephrology Authors: Hicham Skali, Julie Lin, Marc A. Pfeffer, Chao-Yin Chen, Mark E. Cooper, John J.V. McMurray, Allen R. Nissenson, Giuseppe Remuzzi, Jerome Rossert, Patrick S. Parfrey, Nairne W. Scott-Douglas, Ajay K. Singh, Robert Toto, Hajime Uno, Peter Ivanovich Tags: Dialysis Source Type: research
